Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Trial Type:  Treatment
Keywords/Phrases:  signal transduction inhibitor
Results 1-25 of 1814 for your search:
Start Over
PF-04449913 Single-Agent In Patients With Myelofibrosis Previously Treated With a Janus Kinase Inhibitor
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: B1371013, NCI-2014-02538, 2014-000933-21, 2014-001048-40, SMOI, NCT02226172
Phase II Hedgehog Inhibitor for Myelodysplastic Syndrome (MDS)
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 17302, NCI-2013-01758, NCT01842646
A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf, and Erivedge Treatment Targeted Against Certain Mutations in Cancer Patients
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: ML28897, NCI-2014-01811, NCT02091141
A Combination Study of PF-04449913 and Azacitidine In 1st Line MDS, AML and CMML Patients
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: B1371012, NCI-2015-00462, 2014-001345-24, NCT02367456
A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: B1371003, NCI-2012-01145, 2012-000684-24, NCT01546038
Vismodegib in Treating Patients with Orbital or Periocular Basal Cell Carcinoma
Phase: Phase IV
Type: Treatment
Age: 18 and over
Trial IDs: UMCC 2014.022, NCI-2015-00927, ML29160, NCT02436408
Gemcitabine Hydrochloride, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, and Erismodegib before Surgery in Treating Patients with Borderline Resectable Pancreatic Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: J1130, NCI-2012-00064, CIR00003888, LDE225XUS03T, NA_00047491, NA_00047491 / CIR00004443, NCT01431794
Erismodegib and Everolimus in Treating Patients with Advanced Gastroesophageal Cancer
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 2013-0838, NCI-2014-01455, NCT02138929
Erismodegib, Etoposide, and Cisplatin as First-Line Therapy in Treating Patients with Extensive Stage Small Cell Lung Cancer
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 11-206, NCI-2012-00568, NCT01579929
PF-04449913 in Treating Patients with Acute Leukemia or Myelodysplastic Syndromes at High Risk of Relapse after Donor Stem Cell Transplant
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 12-1558, NCI-2013-00824, 12-1558.cc, NCT01841333
Erismodegib in Treating Patients with High-Risk Localized Prostate Cancer
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: J1402, NCI-2014-02144, LDE225XUS13T, NA_00091602, NCT02111187
Itraconazole in Preventing Blood Vessel Growth in Patients with Non-small Cell Lung Cancer Undergoing Surgery
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: SCCC-01515, NCI-2015-00458, NCT02357836
Phase IB/II Trial of LDE225 and Paclitaxel in Recurrent Ovarian Cancer
Phase: Phase II, Phase I
Type: Treatment
Age: 19 and over
Trial IDs: F140214007 (UAB 1357), NCI-2015-00264, 000505867, NCT02195973
A Dose Escalation Study of OMP-52M51 in Subjects With Lymphoid Malignancies
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 90
Trial IDs: 52M51-001, NCI-2013-00503, NCT01703572
Safety and Efficacy Study of PRI-724 in Subjects With Advanced Myeloid Malignancies
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: PRI-724-201, NCI-2012-01153, NCT01606579
Azacitidine and Erismodegib in Treating Patients with Myeloid Malignancies
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MC1389, NCI-2014-00866, Mod13-009003-08, NCT02129101
Itraconazole in Treating Patients with Basal Cell Carcinoma
Phase: No phase specified
Type: Treatment
Age: 18 and over
Trial IDs: J1299, NCI-2014-01255, NA_00077461, NCT02120677
Vismodegib in Treating Patients with Hormone-Resistant Metastatic Prostate cancer
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: J1423, NCI-2014-02512, Vismodegib, NCT02115828
Safety and Efficacy Study of PRI-724 Plus Gemcitabine in Subjects With Advanced or Metastatic Pancreatic Adenocarcinoma
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: PRI-724-102, NCI-2013-00907, NCT01764477
Radiation Therapy and Vismodegib in Treating Patients With Locally Advanced Head and Neck Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: CC #122011, NCI-2013-00871, 122011, NCT01835626
Erismodegib and Lenalidomide after Stem Cell Transplant in Treating Patients with Multiple Myeloma
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: MC128B, NCI-2014-00170, NCT02086552
Erismodegib in Treating Patients with Advanced or Metastatic Liver Cancer That Cannot Be Removed by Surgery or Child-Pugh A Cirrhosis
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CLDE225XUS12T, NCI-2014-01762, 131053, HRPP #131053, NCT02151864
A Study of Vantictumab (OMP-18R5) in Combination With Docetaxel in Patients With Previously Treated NSCLC
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 18R5-004, NCI-2013-01405, NCT01957007
Sirolimus and Vismodegib in Treatment of Patients with Solid Tumors or Pancreatic Cancer That is Metastatic or Cannot Be Removed by Surgery
Phase: Phase I
Type: Biomarker/Laboratory analysis, Diagnostic, Treatment
Age: 18 and over
Trial IDs: MC1111, NCI-2011-03809, NCT01537107
Start Over